ZYME's Quality Score rose 1 point on Fri, Oct 30, to 7. Traded heavy volume (2 chart checks started).
Follow ZYME's trial news. Pro members can get an alert when Zymeworks files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 309% over three years while the S&P 500 rose 89%.
“Total revenue increased by $29.7 million in 2025 compared to 2024, due to higher revenue recognized across multiple partnered programs.”
| The chart | Stronger than 85% of stocks |
| Latest filing | 8-K, Oct 23 |
ReportReports Mon Nov 9, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, -4.1% on average. Past reports ›
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
ZYME closed −0.8% that day.
Wed Nov 11: Stifel Healthcare Conference 2026Investor conference · date confirmed.
5 more dates ahead: conferences and the meeting, for Pro members.
After its last 4 reports it closed -4.1% on average, higher 2 of 4 times.
About 10 quarters
EVP, Head of R&D Adam Schayowitz sold 13,832 shares on Oct 9. 7 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Averagefor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. ZYME scores 7 today, against a median of 3 over its last 20 recorded sessions.
ZYME is #22 of 92 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 22 |
Share count against a year before: ZYME -3.1%, NRIX +33%, IMNM +30%, PTCT +6.2%.
Reports Mon Nov 9, after the close (in 7 days). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The decrease was driven mainly by absence of significant non-recurring collaboration revenue recognized in 2026, as well as continued declines in development support and drug supply revenue from Jazz.”
ZYME's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The change in 2026 was primarily due to a decrease in revenue, driven by the non-recurring clinical milestones earned in 2Q-2025 and interest expense related to the royalty-backed note financing arrangement with Royalty Pharma.”
From its results filing (SEC filing · Aug 6)
Sales fell 36% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 8.4% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 6, 2026 | +4.2% | +1.8% | +11.4% |
| May 7, 2026 | -1.5% | -10.2% | -9.9% |
| Mar 2, 2026 | -3.2% | +0.1% | +3.4% |
Sales grew in three of the last five years, to $106M in 2025. It made a profit in one of the six years.
One insider sold $358K across 1 filing in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ZYME is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
“The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products.”
ZYME scores 7 today, which Breakaway calls Average. It is #22 of 92 in Pharma by Quality Score, with 6 of 14 chart checks firing. Up 309% over three years while the S&P 500 rose 89%. Cash lasts about 10 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ZYME scores 7 today, which Breakaway calls Average (6 to 10). That is #22 of 92 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ZYME's 7.
One insider sold $358K across 1 filing in the last 6 months. No open-market buys on record. The newest is Adam Schayowitz, EVP, Head of R&D, who sold $358K on Oct 9.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.